1347 GMT - The consumer-health industry could see more merger-and-acquisition activity, but smaller deals for certain brands or segments seem more likely than large-scale takeovers, Citi analysts say in a research note. Recent spinoffs such as Kenvue and Haleon, potential splits or asset reviews at Bayer and Reckitt Benckiser, and acquisition attempts like Unilever's for Haleon in 2022 left investors wondering whether the industry could consolidate, Citi says. Healthy balance sheets and interest from the likes of Procter & Gamble suggest there is room for acquisitions, but antitrust concerns and diverse portfolios make large deals unlikely, Citi says. In a large takeover, the buyer would probably need a significant portfolio reshaping afterward, the analysts say. The Stoxx Europe 600 Personal & Household Goods index is up 0.6%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 30, 2025 09:47 ET (13:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.